Then, an intermediate host (the larval stage of a flea or chewing louse) will ingest an egg, which develops into a cysticercoid larva. The cysticercoid larva remains viable, but is not infective to carnivores until the flea hatches to an adult and begins feeding on a host (e.g. a dog). Approximately 36 hours after the flea has consumed a blood meal, the infective metacestode develops inside the flea. The metacestode larva must be ingested in a flea by the dog or cat during grooming in order to develop. Humans can also become infected by D. caninum by accidentally ingesting an infected flea. In the small intestine of the definitive host, the metacestode develops into an adult tapeworm, which reaches maturity 4-6 weeks after ingestion. This adult tapeworm produces proglottids, and over time, the proglottids mature and become gravid and eventually detach from the tapeworm and the life cycle starts all over again. Geographic Distribution
This parasite occurs worldwide in animals, such as dogs and cats, as well as in humans, though to a significantly lesser degree. It is the most common tapeworm of dogs and is relatively common in cats. Despite human diplydiasis being rare, instances have been reported from every inhabited continent.Human instances of diplydiasis are reported globally, and unsurprisingly roughly one third of the cases occur in children less than 6 months of age. The most at-risk age group is those that range from 2 months to 4 years old.
Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation. Mechanism of action
The drug functions as a motility stimulant, achieving its desired therapeutic effects through activation of the 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract. It also stimulates gastrointestinal motility and the peristaltic reflex, and allegedly reduces abdominal pain. Additionally, tegaserod is a 5-HT2B receptor antagonist. Withdrawal from market
On 30 March 2007, the United States Food and Drug Administration requested that Novartis withdraw tegaserod from shelves. The FDA alleged a relationship between prescriptions of the drug and increased risks of heart attack or stroke. An analysis of data collected on over 18,000 patients demonstrated adverse cardiovascular events in 13 of 11,614 patients treated with tegaserod (a rate of 0.11%) as compared with 1 of 7,031 patients treated with placebo (a rate of 0.01%). Novartis alleged all of the affected patients had preexisting cardiovascular disease or risk factors for such, and further alleged that no causal relationship between tegaserod use and cardiovascular events has been demonstrated.